使用基于MHC II类分子和B7.1细胞的肿瘤疫苗对已形成的肿瘤进行免疫治疗。 - Suppr | 超能文献

Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines.

作者信息

Ostrand-Rosenberg S, Pulaski B A, Armstrong T D, Clements V K

机构信息

Department of Biological Sciences, University of Maryland, Baltimore 21250, USA.

出版信息

Adv Exp Med Biol. 1998;451:259-64. doi: 10.1007/978-1-4615-5357-1_42.

DOI:10.1007/978-1-4615-5357-1_42

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines.使用基于MHC II类分子和B7.1细胞的肿瘤疫苗对已形成的肿瘤进行免疫治疗。

Adv Exp Med Biol. 1998;451:259-64. doi: 10.1007/978-1-4615-5357-1_42.

2

Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.将MHC II类/CD80+肿瘤细胞与白细胞介素-12相结合的疫苗免疫疗法可减少已形成的转移性疾病，并刺激免疫效应细胞和干扰素γ诱导的单核因子。

Cancer Immunol Immunother. 2000 Apr;49(1):34-45. doi: 10.1007/s002620050024.

3

Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.使用基于主要组织相容性复合体II类和B7.1细胞的肿瘤疫苗进行免疫治疗后，已建立的自发性乳腺癌转移灶减少。

Cancer Res. 1998 Apr 1;58(7):1486-93.

4

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.基于MHC II类分子和CD80的肿瘤细胞疫苗是1型CD4+ T淋巴细胞的有效激活剂，前提是它们不共表达恒定链。

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. doi: 10.1007/s00262-003-0486-4. Epub 2004 Jan 17.

5

Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.MHC II类分子以及共刺激分子B7-1和B7-2的表达伴随着肿瘤排斥反应，并降低肿瘤细胞的转移潜能。

Tissue Antigens. 1996 May;47(5):414-21. doi: 10.1111/j.1399-0039.1996.tb02577.x.

6

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.CTLA-4阻断与肿瘤来源的粒细胞-巨噬细胞集落刺激因子协同作用，用于治疗实验性乳腺癌。

Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10067-71. doi: 10.1073/pnas.95.17.10067.

7

Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.通过II类相关恒定链肽的基因交换，携带肿瘤特异性辅助性T细胞表位的细胞疫苗诱导出更强的肿瘤保护作用。

Cancer Res. 2000 Nov 15;60(22):6427-33.

8

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.B7的组成型表达可恢复表达截短的主要组织相容性复合体II类分子的肿瘤细胞的免疫原性。

Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5687-90. doi: 10.1073/pnas.90.12.5687.

9

Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.IFN-γ B7.1与反义TGF-β基因转移对低免疫原性转移性乳腺癌致瘤性的比较分析

Cancer Immunol Immunother. 2001 Jul;50(5):229-40. doi: 10.1007/s002620100197.

10

Simultaneous expression of allogenic class II MHC and B7.1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity.

Mol Cells. 2002 Feb 28;13(1):130-6.

引用本文的文献

1

Passage Number of 4T1 Cells Influences the Development of Tumour and the Progression of Metastasis in 4T1 Orthotopic Mice.4T1细胞的传代次数影响4T1原位小鼠肿瘤的发展和转移进程。

Malays J Med Sci. 2022 Jun;29(3):30-42. doi: 10.21315/mjms2022.29.3.4. Epub 2022 Jun 28.